Avacta Group plc (AIM: AVCT) (“Avacta”), the developer of Affimer® biotherapeutics and reagents, and Mologic Ltd (“Mologic”) today announced that they have entered into a commercial partnership to accelerate to market Avacta’s AffiDX™ SARS-CoV-2 lateral flow rapid antigen test. Avacta will also support antigen testing in low and middle income countries[1] by providing access to Avacta’s spike antigen test through Mologic.

Mologic is a leading developer of lateral flow and rapid diagnostic technologies, products and services. We work with companies, researchers and clinicians to help them deliver fast, reliable and accurate diagnosis at the point-of-care.

Our Co-founder and Chief Scientific Officer, Paul Davis, was the originator of the Clearblue pregnancy test. Launched in 1988, it was the world’s first commercial application of lateral flow technology. The creativity, insight and knowledge that led to that ground-breaking invention has guided Mologic since our formation in 2003.

Mologic offers you an extensive portfolio of device and reagent products for clinical and commercial applications along with world-leading scientific research expertise for your contract R&D requirements.